OpGen, Inc. (Nasdaq:OPGN), an early commercial stage molecular
testing and bioinformatics company, today announced that new study
data on its Acuitas® MDRO Gene Test, Acuitas CR Elite Test, and
Acuitas Lighthouse™ MDRO Management System will be presented at the
115th General Meeting of the American Society of Microbiology, to
be held from May 30 to June 2 in New Orleans. OpGen will host a
satellite symposium, entitled "Standing Up to Superbugs:
Technologies to Improve Management of Multi-drug Resistant
Organisms," during the ASM2015 meeting.
"The research results from the OpGen product-related posters
that will be presented at ASM2015 underscore the critical need for
faster, more accurate ways for hospitals, healthcare systems, and
public health agencies to detect multidrug resistant organisms
(MDROs), and determine the genetic variability that guides the
organisms' behavior and ability to cause infection," said Terry
Walker, PhD, OpGen Senior Vice President, Research &
Development. "We are excited to share data that can demonstrate how
the Acuitas suite of products can be useful to hospital
administrators and infection control professionals. We are also
pleased to host a symposium that will help to shed more light on
the importance of combining high resolution genetics and
bioinformatics to improve management of MDROs."
Details for the four posters, and when they will be presented,
follow:
1. Strain Typing and High
Resolution Analysis of Antibiotic Resistance in Multidrug-Resistant
Organisms (MDROs) by Whole Genome Sequencing. Poster
Session 038. Antimicrobial Resistance and Susceptibility Testing:
Gram-Negative (Division C), Sun, May 31, 12:30 - 1:45 PM Central
time. OpGen's Acuitas Whole Genome Sequence Analysis using
multilocus sequence typing (MLST+) analysis of 2,300 genes was
compared to the Whole Genome Mapping™ System in resolving closely
related clinical strains of E. coli and K. pneumoniae.
2. Acuitas CR Elite and
Acuitas Lighthouse – A Genetic, Phenotypic and Bioinformatics
Solution for Typing and Tracking MDROs. Poster Session
038. Antimicrobial Resistance and Susceptibility Testing:
Gram-Negative (Division C), Sun, May 31, 12:30 - 1:45 PM Central
time. The Acuitas CR Elite PCR-based assay and phenotype test,
combined with the Acuitas Lighthouse MDRO Management System, in
development, was used to test 500+ samples from seven hospitals to
detect specific genes for antibiotic resistance.
3. The Detection of
Carbapenemases in Carbapenem-Resistant Gram-Negative Bacteria from
an Academic Medical Center. Poster Session 098.
Identification/Detection: Multiplex I (Division C), Mon, Jun 1,
10:45 AM - 12:00 PM Central time. The Acuitas MDRO Gene Test was
used to identify specific resistance genes testing clinical
isolates from the University of Maryland Medical Center, including
the ability to rank genes according to degree of resistance to
antibiotics.
4. Comparing Culture
Based Methods to a Novel PCR-Based Multiplex Assay to Detect
Carbapenemase Genes in Perirectal Swabs. Poster Session
124. Identification/Detection: Multiplex II (Division C), Mon, Jun
1, 12:30 - 1:45 PM Central time. The Acuitas CR Elite Test was
measured against the U.S. Centers for Disease Control and
Prevention (CDC) protocol based on cell culture in detecting
carbapenemase-resistant enterococcus (CRE) in patients at Detroit
Medical Center.
OpGen will host a satellite symposium, entitled "Standing Up to
Superbugs: Technologies to Improve Management of Multi-drug
Resistant Organisms," during the ASM2015 meeting on Monday, June 1,
from 6:30-8:30 p.m. Central time at the Downtown Marriott Hotel in
New Orleans. Topics and speakers include:
Managing Patients at Risk for
MDRO Colonization and Infection Keith S. Kaye, MD, MPH,
Professor of Medicine Corporate Vice President of Quality and
Patient Safety Corporate Medical Director, Infection Prevention,
Epidemiology and Antimicrobial Stewardship Detroit Medical Center
and Wayne State University, University Health Center
Real-Time Genome Sequencing of
Multidrug-Resistant Bacteria Enables Cost-Effective High Resolution
Detection and Refutation of Nosocomial Transmissions
Dag Harmsen, MD, Professor of Medical Microbiology, University of
Münster, Germany
The Benefits of Molecular
Screening and Surveillance for MDROs Lance R.
Peterson, MD, Director of Microbiology and Infectious Diseases
Research Epidemiologist Departments of Pathology/Lab Medicine and
Medicine, NorthShore University HealthSystems Clinical Professor
University of Chicago Pritzker School of Medicine
Advancing MDRO DNA Detection
& Bioinformatics: Acuitas® MDRO Tests and New Developments from
OpGen Terry Walker, PhD, Sr. Vice President, R&D
OpGen
About MDROs
Multi-drug resistant organisms (MDROs) are common bacteria that
have developed resistance to multiple classes of antibiotics. They
are a leading cause of hospital-acquired infections and are
associated with an increase in morbidity and mortality. Each year,
more than two million Americans acquire infections that are
resistant to antibiotics and of those, 23,000 will die of those
infections. Asymptomatic carriers are at a higher risk of an MDRO
infection and become reservoirs for transmission to other patients
in health care systems if not accurately identified early. Since
there are many types of antibiotic resistant organisms, and the way
they cause disease is dictated by their genetics, knowing the exact
genetic profile of these organisms is a key step to preventing
their ability to infect.
About OpGen
OpGen, Inc. is an early commercial stage company using molecular
testing and bioinformatics to assist healthcare providers in
combating multi-drug resistant bacterial infections. The company's
products and services are designed to enable the rapid
identification of hospital patients who are colonized or infected
with life-threatening, multi-drug resistant organisms, or MDROs.
The company's lead product is the Acuitas MDRO Gene Test. Products
in development include the Acuitas Lighthouse MDRO Management
System and the Acuitas Resistome Test. In addition, the company has
more than 10 years of experience mapping microbial, plant and human
genomes. Learn more at www.opgen.com.
CONTACT: OpGen
Michael Farmer
Director, Marketing
(240) 813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com
Media
Lisa Guiterman
(301) 217-9353
lisa.guiterman@gmail.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024